Richard Marais

Cancer Research UK Manchester Institute — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

99h-index48.4kcitations625works15.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(261), Cancer Genomics and Diagnostics(67), Protein Kinase Regulation and GTPase Signaling(57), Cutaneous Melanoma Detection and Management(55), Synthesis and biological activity(52)

Publications623 total

SOX2 confers tumour permissiveness in a specific skin progenitor population
Nature Communications·2026Open Access
Abstract 1735: The discovery of PKMYT1 inhibitors to exploit synthetic lethality caused by replication stress
Cancer Research·2025
SOX2 empowers a rapid tumorigenic programme from the tumour-resistant population in the skin
2025Open Access
ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma
Cell Reports·2024· 2 citedOpen Access
345 (PB333): Discovery of novel series of PKMYT1 inhibitors forcombination therapy with antibody-drug conjugates
European Journal of Cancer·2024
ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma
Cell Reports·2024· 12 citedOpen Access
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
Cell Reports Medicine·2024· 18 citedOpen Access
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Nature Medicine·2024· 109 citedOpen Access
Frequency of naevus cells in lymph nodes of melanoma and breast cancer patients
Pathology - Research and Practice·2024Open Access
ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma
2023· 1 citedOpen Access
Longitudinal gut microbiome changes in immune checkpoint blockade in advanced melanoma
2023Open Access
Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation
Scientific Reports·2023· 3 citedOpen Access
Prognosis of naevoid melanomas
Pathology - Research and Practice·2023Open Access
2236P MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Annals of Oncology·2023Open Access
P56 Trial redesign for the phase II/III DETECTION trial: circulating tumour DNA-guided therapy for stage IIB/C melanoma after surgical resection
British Journal of Dermatology·2023· 2 citedOpen Access
The journey from melanocytes to melanoma
Nature reviews. Cancer·2023· 156 cited
Supplementary Table S2 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Data from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic <i>NRAS</i> in Melanocytes
2023Open Access
Supplementary Figures S1-S7 from <i>SF3B1</i> Mutations Are Associated with Alternative Splicing in Uveal Melanoma
2023Open Access
Supplementary Materials, Figures 1-7, Table 1 from Metformin Accelerates the Growth of BRAF<sup>V600E</sup>-Driven Melanoma by Upregulating VEGF-A
2023Open Access
page 1 of 32Next →

Frequent Co-authors

Caroline J. Springer(10), Nathalie Dhomen(8), Christopher J. Marshall(7), Amaya Virós(7), Claudia Wellbrock(6), María Romina Girotti(6), Mathew J. Garnett(5), Hugh Paterson(5), Dan Niculescu‐Duvaz(5), Keith T. Flaherty(5), Robert Hayward(5), Maria Karasarides(4), Erik Sahai(4), Yvonne Light(4), James Larkin(4), Simon J. Furney(4), Malin Pedersen(4), Paul Lorigan(4), Berta Sanchez‐Laorden(4), Steven Hooper(3)